LIR Life Sciences Corp. is a biopharmaceutical company focused on developing transdermal delivery systems for obesity and metabolic disorders. The company faces significant concerns, including a very low current ratio of 0.04, indicating liquidity issues, and a negative return on assets of -117.9%, suggesting inefficiency in asset utilization. With a market cap of only $3.73 million and no price movement today, investor interest appears limited, raising questions about its growth potential and financial stability. Overall, while the innovative focus is promising, financial health remains a critical concern.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q3 (July 31, 2025)